Who are Paroxetine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lexapro, Prozac, escitalopram and sertraline, High severity group: Escitalopram, sertraline fluvoxamine, Zoloft tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paroxetine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Paroxetine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paroxetine (paroxetine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective Serotonin Reuptake Inhibitor (SSRI). Area: Neuroscience.

marketed Selective Serotonin Reuptake Inhibitor (SSRI) Serotonin (5-HT) reuptake transporter Neuroscience Live · refreshed every 30 min

Target snapshot

Paroxetine (paroxetine) — Pfizer Inc.. Inhibits neuronal reuptake of serotonin in the central nervous system, presumed mechanism for treating psychiatric disorders.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Paroxetine TARGET	paroxetine	Pfizer Inc.	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin (5-HT) reuptake transporter
Lexapro	escitalopram	Generic (originally Lundbeck/Forest)	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin (5-HT) reuptake transporter	2002-08-14
Prozac	fluoxetine	Eli Lilly and Company	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter	1987-12-29
escitalopram and sertraline	escitalopram and sertraline	Oregon Health and Science University	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
High severity group: Escitalopram	High severity group: Escitalopram	University of Texas Southwestern Medical Center	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
sertraline fluvoxamine	sertraline fluvoxamine	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Zoloft tablets	Zoloft tablets	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective Serotonin Reuptake Inhibitor (SSRI) class)

Eli Lilly and Company · 1 drug in this class
Generic (originally Lundbeck/Forest) · 1 drug in this class
Pfizer Inc. · 1 drug in this class
University of Pennsylvania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paroxetine — Competitive Intelligence Brief. https://druglandscape.com/ci/paroxetine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing